What are the core DSM-5 clinical criteria for Major Depressive Disorder?
Master all 24 flashcards
Mastering this deck enables you to recognize neurochemical underpinnings of anxiety and mood disorders, improving diagnostic accuracy and informing targeted pharmacological interventions in clinical practice.
Showing 20 of 24 cardsSample view
| # | Front | Back | Hint |
|---|---|---|---|
| 1 | What are the core DSM-5 clinical criteria for Major Depressive Disorder? |
Master all 24 flashcards
Explore other decks you might find helpful
Learn DSM-5 criteria with neurochemical insights, linking chemical imbalances to clinical symptoms for diagnosis and treatment.
The DSM-5 criteria for Major Depressive Disorder include at least five of the following symptoms present during the same 2-week period: depressed mood, loss of interest or pleasure, significant weight change or appetite disturbance, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, feelings of worthlessness or excessive guilt, diminished ability to think or concentrate, and recurrent thoughts of death or suicide. At least one symptom must be depressed mood or anhedonia. |
| Think of 'SIGECAPS'—Sleep, Interest, Guilt, Energy, Concentration, Appetite, Psychomotor, Suicide. |
| 2 | Which neurochemical imbalance is most commonly associated with depression? | Decreased levels of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) are commonly associated with depression, contributing to mood dysregulation, anhedonia, and low energy. | Serotonin is often the primary focus in depression research and treatment. |
| 3 | What neurochemical alterations are linked to Generalized Anxiety Disorder (GAD)? | GAD is associated with dysregulation of gamma-aminobutyric acid (GABA), leading to decreased inhibitory signaling, and often involves heightened noradrenaline activity, resulting in increased arousal and worry. | GABA is the brain’s primary inhibitory neurotransmitter—think 'brake' for anxiety. |
| 4 | How does serotonin dysregulation contribute to anxiety disorders? | Serotonin dysregulation, particularly decreased serotonergic activity, can impair the regulation of mood and anxiety, leading to heightened fear responses and worry, as seen in disorders like panic disorder and GAD. | Serotonin acts as a 'dampening' agent for excessive fear responses. |
| 5 | What is the role of norepinephrine in the pathophysiology of mood and anxiety disorders? | Norepinephrine is involved in arousal, alertness, and stress response; hyperactivity can contribute to anxiety symptoms, while hypoactivity has been linked to depression. | Think of norepinephrine as the 'alarm system'—overactive alarms can cause anxiety. |
| 6 | Describe the neurochemical basis of panic attacks in terms of neurotransmitter activity. | Panic attacks are associated with sudden surges in noradrenaline and dysregulation of GABA, resulting in hyperarousal and intense fear; serotonin imbalance may also play a role. | Surge = 'alarm' in the nervous system. |
| 7 | Which neurochemical systems are primarily targeted by SSRIs in the treatment of depression and anxiety? | SSRIs (Selective Serotonin Reuptake Inhibitors) target the serotonergic system by increasing serotonin availability in synapses, helping to regulate mood and reduce anxiety symptoms. | SSRI = 'Serotonin Sustainer.' |
| 8 | How do neurochemical imbalances differ between unipolar depression and bipolar disorder? | Unipolar depression typically involves deficits in serotonin, norepinephrine, and dopamine, whereas bipolar disorder involves dysregulation of these neurotransmitters, with episodes of both depression and mania linked to increased norepinephrine and dopamine activity during mania. | Think of mood swings as 'neurochemical rollercoasters.' |
| 9 | What is the significance of the HPA axis in mood and anxiety disorders? | Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis leads to abnormal cortisol levels, which are linked to increased stress sensitivity, depression, and anxiety symptoms. | HPA axis = 'stress response' system. |
| 10 | Which neurochemical changes are associated with treatment-resistant depression? | Reduced function of serotonergic, noradrenergic, and dopaminergic systems, along with increased neuroinflammation and HPA axis hyperactivity, may contribute to resistance to standard treatments. | Resistance may involve multiple chemical pathways. |
| 11 | How does neurochemical research inform pharmacological treatment of anxiety and mood disorders? | Understanding neurotransmitter dysregulation guides the use of medications like SSRIs, SNRIs, benzodiazepines, and mood stabilizers that target specific neurochemical pathways to restore balance and alleviate symptoms. | Targeted medications 'rebalance' the brain's chemistry. |
| 12 | What is the neurochemical explanation for the effectiveness of benzodiazepines in anxiety disorders? | Benzodiazepines enhance GABA-A receptor activity, increasing inhibitory signaling and producing a calming effect, counteracting GABA deficits associated with anxiety. | Benzos = 'GABA enhancers.' |
| 13 | In what way are neurochemical factors involved in the comorbidity of depression and anxiety? | Shared deficits in serotonin and GABA dysregulation can underlie both conditions, explaining their frequent co-occurrence and similar responses to serotonergic and GABAergic medications. | Common neurochemical pathways link these disorders. |
| 14 | Explain how neurochemical imbalances can influence the clinical presentation of Persistent Depressive Disorder (Dysthymia). | Chronic low levels of serotonin, norepinephrine, and dopamine can produce a persistent, milder depressive mood characteristic of dysthymia, with ongoing deficits affecting motivation and mood stability. | Chronic chemical deficits produce 'persistent low mood.' |
| 15 | What role does neuroinflammation play in mood disorders according to recent neurochemical research? | Neuroinflammation involving cytokines and microglial activation can disrupt neurotransmitter systems (serotonin, dopamine), contributing to depression and treatment resistance. | Inflammation impacts brain chemistry. |
| 16 | How do neurochemical theories of anxiety and depression explain the efficacy of combination pharmacotherapy? | Combination treatments target multiple neurotransmitter systems (e.g., serotonin, norepinephrine, GABA) to address complex neurochemical dysregulation and improve symptom control. | Multi-target approach for complex imbalances. |
| 17 | What is the relationship between neurochemical imbalance and suicidal ideation in mood disorders? | Reduced serotonergic activity, especially in prefrontal regions, is linked to increased impulsivity and suicidal behavior, highlighting the importance of serotonin in mood regulation. | Serotonin deficiency linked to impulsivity. |
| 18 | Which neurochemical systems are implicated in the psychomotor agitation seen in depression? | Dysregulation of dopamine and norepinephrine pathways can lead to psychomotor agitation, including restlessness and fidgeting. | Dopamine influences movement and motivation. |
| 19 | Identify a neurochemical change that is often observed during manic episodes in bipolar disorder. | Elevated dopamine activity and increased norepinephrine levels are commonly observed during mania, contributing to heightened energy, euphoria, and impulsivity. | Dopamine surge = mania. |
| 20 | How does chronic stress influence neurochemical systems involved in anxiety and depression? | Chronic stress activates the HPA axis, elevating cortisol levels, which can damage serotonergic and hippocampal function, exacerbating symptoms of anxiety and depression. | Stress = 'chemical imbalance' via cortisol. |
Note: This preview shows only the first 20 cards. The complete deck contains 24 total cards. Start studying to access all flashcards.